Ra Medical Systems to Report 2020 Fourth Quarter and Full Year Financial Results on March 16, 2021

Rhea-AI Summary

Ra Medical Systems (NYSE: RMED) will report its 2020 Q4 and full-year financial results after market close on March 16, 2021. The management team will host a conference call for the investment community at 1:30 PM PT to discuss results and provide company updates. Participants can pre-register for immediate access or join live by calling specified numbers. Ra Medical specializes in excimer laser technology for treating vascular and dermatological diseases, with FDA-cleared products like DABRA and Pharos.

Positive

• Upcoming reporting of 2020 Q4 and full-year results could provide insights into financial performance.
• Management will provide a business update during the conference call.

Negative

• None.

Ra Medical Systems, Inc. (NYSE: RMED) announces that it will report 2020 fourth quarter and full year financial results and provide a business update after market close on Tuesday, March 16, 2021. Ra Medical management will hold an investment community conference call that day at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) to discuss financial results and provide a company update.

Pre-Registration		Participants can pre-register for the conference call here.
		Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator. Participants may pre-register at any time, including up to and after the call start time.
Live Call:		Those who choose not to pre-register can access the live conference by dialing:
		U.S.	866-777-2509
		International	412-317-5413
		Passcode	10152763
Live Webcast:		Ra Medical Website
		The webcast will be archived for 30 days.
Replay:		U.S.	877-344-7529
		Canada	855-669-9658
		International	412-317-0088
		Passcode	10152763
		The replay will be available for 48 hours.

About Ra Medical Systems

Ra Medical Systems commercializes excimer lasers and catheters for the treatment of vascular and dermatological diseases. In May 2017 the DABRA excimer laser system received FDA 510(k) clearance in the U.S. for crossing chronic total occlusions, or CTOs, in patients with symptomatic infrainguinal lower extremity vascular disease with an intended use for ablating a channel in occlusive peripheral vascular disease. The Pharos excimer laser system is FDA-cleared and is used as a tool in the treatment of psoriasis, vitiligo, atopic dermatitis and leukoderma. DABRA and Pharos are both based on Ra Medical’s core excimer laser technology platform and deploy similar mechanisms of action. Ra Medical manufactures DABRA and Pharos excimer lasers and catheters in a 32,000-square-foot facility located in Carlsbad, Calif. The vertically integrated facility is ISO 13485 certified and is licensed by the State of California to manufacture sterile, single-use catheters in controlled environments.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210309005280/en/

FAQ

When will Ra Medical Systems release its 2020 Q4 financial results?

Ra Medical Systems will report its 2020 Q4 financial results on March 16, 2021.

What time is the conference call for Ra Medical Systems' financial results?

The conference call is scheduled for 1:30 PM PT on March 16, 2021.

How can I participate in the Ra Medical Systems conference call?

Participants can pre-register for the conference call or dial in using the provided U.S. or international numbers.

What products does Ra Medical Systems offer?

Ra Medical Systems offers excimer laser systems like DABRA and Pharos for treating vascular and dermatological diseases.